Pfizer is a research-based biopharmaceutical company, developing and manufacturing human and veterinary medicines, as well as consumer healthcare products. The Company applies science and its global resources to improve health and well-being at every stage of life. Its diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products, and many consumer health care products. The Company operates in two business segments: biopharmaceutical and diversified. Biopharmaceutical segment includes the primary and specialty care, established products, emerging markets and oncology customer-focused units. Diversified segment offers animal health products that prevent and treat diseases in livestock and companion animals, and consumer healthcare products. Pfizer develops and produces medicines and vaccines for a wide range of conditions including in the areas of immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain. 

Show more
New York, US
Size (employees)
90,200 (est)-6%
Pfizer was founded in 1849 and is headquartered in New York, US
Report incorrect company information

Key People/Management at Pfizer

Ian C. Read

Ian C. Read

Chairman of the Board and Chief Executive Officer
Albert Bourla

Albert Bourla

Chief Operating Officer, Pfizer
Frank D'Amelio

Frank D'Amelio

Executive Vice President, Business Operations and Chief Financial Officer
Mikael Dolsten

Mikael Dolsten

President, Worldwide Research and Development of Pfizer Inc
Michael Goettler

Michael Goettler

Executive Vice President, Pfizer
Angela Hwang

Angela Hwang

Group President, Pfizer Essential Health
Show more

Pfizer Office Locations

Pfizer has offices in Surrey, Zürich, Sollentuna, Alcobendas and in 36 other locations
New York, US (HQ)
235 E 42nd St
Buenos Aires, AR
Panamericana Collector 1804, 1st Floor - Sector B - South Side
Melrose Park, AU
38-42 Wharf Rd
Wien, AT
1 Floridsdorfer Hauptstraße
Minsk, BY
403 8 praspiekt Dziaržynskaha
Ixelles, BE
17 Boulevard de la Plaine
Show all (40)
Report incorrect company information

Pfizer Financials and Metrics

Pfizer Revenue

Embed Graph
Pfizer's revenue was reported to be $52.82 b in FY, 2016 which is a 8.1% increase from the previous period.

Revenue (Q2, 2019)

26.4 b

Gross profit (Q2, 2019)

20.9 b

Gross profit margin (Q2, 2019), %


Net income (Q2, 2019)

7.4 b

Market capitalization (16-Aug-2018)

242.8 b

Closing stock price (16-Aug-2018)


Cash (1-Jul-2018)

2.7 b


269 b
Pfizer's current market capitalization is $242.8 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


51.6 b49.6 b48.9 b52.8 b

Revenue growth, %


Cost of goods sold

9.6 b9.6 b9.6 b12.3 b

Gross profit

42 b40 b39.2 b40.5 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q2, 2017Q1, 2019Q2, 2019


12.6 b11.4 b12.8 b12.4 b10.9 b11.9 b12.1 b12.9 b12.9 b26.4 b

Cost of goods sold

2.3 b2 b2.5 b2.4 b1.8 b2.6 b5.5 b

Gross profit

10.4 b9.3 b10.3 b10 b9 b10.3 b20.9 b

Gross profit Margin, %

usdY, 2011Y, 2012FY, 2013FY, 2014FY, 2015FY, 2016


3.2 b10.1 b2.2 b3.3 b3.6 b


6.2 b5.7 b

Current Assets

56.2 b57.7 b43.8 b38.9 b


12.4 b11.8 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q1, 2017Q2, 2017Q1, 2019Q2, 2019


2.1 b2.9 b3.4 b2.4 b3.6 b3.7 b3.1 b2.3 b2.7 b


6.5 b6.1 b6.2 b6.4 b5.8 b5.8 b7.6 b7.6 b8.1 b8.1 b

Current Assets

59.5 b57.8 b58.3 b57 b49.4 b51.7 b45 b38.5 b41.3 b43.8 b35.9 b36.4 b34.8 b37.3 b


12.4 b12.3 b12.2 b12 b11.5 b11.4 b13.7 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

22.1 b9.2 b


(538 m)175 m(199 m)365 m

Accounts Payable

382 m297 m254 m871 m

Cash From Operating Activities

17.8 b16.9 b14.5 b15.9 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2017Q1, 2019Q2, 2019

Net Income

2.6 b2.3 b2.9 b2.7 b2.4 b3.6 b7.4 b

Depreciation and Amortization

3.1 b1.6 b3.1 b

Cash From Operating Activities

4.8 b2 b5.8 b

Purchases of PP&E

(806 m)(386 m)(810 m)
USDY, 2018


46.1 x

Financial Leverage

2.4 x
Show all financial metrics

Pfizer Operating Metrics

FY, 2014FY, 2015FY, 2016FY, 2017

Active Clinical Studies

448 338

Phase III Trials Products

22 30 34 29

Discovery Projects

91 90 96 87

Vaccines Delivered

135 m
Show all operating metrics

Pfizer Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Medivation August 22, 2016$14 b
Anacor Pharmaceuticals June 24, 2016$5.20 b
Allergan November 23, 2015$160 b

Pfizer Revenue Breakdown

Embed Graph

Pfizer revenue breakdown by business segment: 18.6% from GIP, 17.0% from VOC, 35.6% from Innovative Products and 28.7% from Established Products GEP

Report incorrect company information

Pfizer Online and Social Media Presence

Embed Graph
Report incorrect company information

Pfizer News and Updates

US Rheumatologists' Early Views on Eli Lilly's Olumiant for the Treatment of Rheumatoid Arthritis Show Uphill Battle, While Pfizer's Xeljanz Holds Ground as the Preferred JAK Inhibitor

EXTON, Pa., Aug. 20, 2018 /PRNewswire/ -- Spherix Global Insights' third quarter update of RealTime Dynamix™: Rheumatoid Arthritis (US) captured initial insights on Eli Lilly's long-awaited launch of Olumiant (baricitinib). While three-quarters of rheumatologists (n=99) are aware of the...

New Research Study on Diclofenac Market: Key Players involved in the research - Auro Laboratories, Henan Dongtai, Bayer, Pfizer, Hunan Warrant, Novartis, Simcere, Merck

A new research study from HTF MI with title Global Diclofenac Market Professional Survey Report 2018 provides an in-depth assessment of the Diclofenac including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies, key players company profiles and strategies. P…

Eye Health Supplements 2018 Global Market Key Players- Vitabiotics Ltd. ,Valeant Pharmaceuticals International Inc. ,Pfizer Inc. ,Alliance Pharma ,The Nature's Bounty Co ,Novartis AG Amway Corp And Forecast To 2023

Wiseguyreports.Com Adds “Eye Health Supplements -Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2023” To Its Research Database. Posted via Industry Today. Follow us on Twitter @IndustryToday

New Frontiers in Cancer Therapies: Focus on Transcription Factors, GTPases, Phosphatases and GPCRs, 2018-2030

LONDON, August 9, 2018 /PRNewswire/ -- INTRODUCTION Cancer therapeutics continues to be one of the most active segments, in terms of drug development efforts, within the pharmaceutical industry. In fact, in the past five years, USFDA has approved more than 70 drugs for the treatment of...

Onychomycosis Market in US Enhancement in Medical Sector and Clinical Aspects 2017

Onychomycosis Market Competitive Analysis, Trends and Forecast till 2021, with free sample copy of the report. Posted via Industry Today. Follow us on Twitter @IndustryToday

Leap Therapeutics Reports Second Quarter 2018 Business Update and Financial Results

CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported a business update and financial results for the second quarter ended June 30, 2018.
Show more
Report incorrect company information

Pfizer Company Life and Culture

Report incorrect company information